The Company advanced its first proprietary product, LCP-Feno, into clinical trials in September 2004. The Company advanced its second proprietary product, LCP-Tacro, into clinical trials in November 2004. LifeCycle Pharma has developed the most efficacious, clinically validated drug-delivery platform for overcoming the deficiencies of drugs with low water-solubility, thus improving the bioavailability of marketed drugs and new chemical entities (NCEs). The resulting novel formulations created by LifeCycle Pharma can better target and remain within the therapeutic index, thus resulting in drugs with significantly improved efficacy and safety profiles. LifeCycle Pharma is collaborating with Recordati S. on a modified-release tablet formulation of Lercanidipine. Lercanidipine is a calcium-channel blocker for hypertension, marketed by Recordati under the brand name Zanidip. LifeCycle Pharma is also collaborating with H. Lundbeck AS on product opportunities in the CNS area.